76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
IDEXX Laboratories Inc
Closed
SectorHealthcare
526.3 -0.36
Overview
Share price change
24h
Min
523.59
Max
531.36
Income | 27M 243M |
|---|---|
Sales | 44M 998M |
P/E Sector Avg | 48.534 50.291 |
EPS | 2.96 |
Profit margin | 24.306 |
Employees | 11,000 |
EBITDA | 54M 352M |
Recommendations | Buy |
|---|---|
12 Months Forecast | -0.45% downside |
Next Earnings | 4 Aug 2025 |
|---|
Market Cap | 4.5B 42B |
|---|---|
Previous open | 526.66 |
Previous close | 526.3 |
News Sentiment
By Acuity
5%
95%
2 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
IDEXX Laboratories Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
IDEXX Laboratories Inc Forecast
Price Target
By TipRanks
-0.45% downside
12 Months Forecast
Average 528 USD -0.45%
High 580 USD
Low 475 USD
Based on 7 Wall Street analysts offering 12 month price targets forIDEXX Laboratories Inc - Dist in the last 3 months.
Sentiment
By Acuity
2 / 380 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
